Printed from Voxsanity (voxsanity.com.au) — NCT06984757 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Parkinsons Disease
Parkinson's Disease Trial, By Invitation
NCT06984757
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Group 1 – Parkinson's disease without cognitive impairment: People aged 18–89 with a Parkinson's disease diagnosis, a memory and thinking score above 26 on a standard test (MoCA), whose Parkinson's medication has been stable, and who can walk independently and make their own decisions.
- Group 2 – Parkinson's disease with mild cognitive impairment: People aged 18–89 with a Parkinson's disease diagnosis, a memory and thinking score of 23–26 on a standard test (MoCA), whose Parkinson's medication has been stable, and who can walk independently and make their own decisions.
- Group 3 – Parkinson's disease with dementia: People aged 18–89 with a Parkinson's disease diagnosis, a memory and thinking score below 23 on a standard test (MoCA), whose Parkinson's medication has been stable, and who can make their own decisions.
- Group 4 – Parkinson's disease with deep brain stimulation (STN-DBS): People aged 18–89 with a Parkinson's disease diagnosis who have working deep brain stimulation devices on both sides of the brain (in the subthalamic nucleus), whose Parkinson's medication has been stable, and who can walk independently and make their own decisions. (Note: this group will not undergo brain stimulation treatment called TMS as part of the trial.)
- Group 5 – Parkinson's disease without deep brain stimulation, for a specific brain wave and brain stimulation study (EEG-TMS): People aged 18–89 with a Parkinson's disease diagnosis, a memory and thinking score of 23–30 on a standard test (MoCA), whose Parkinson's medication has been stable, who can walk independently and make their own decisions, and who have no history of seizures.
- Group 6 – Essential tremor with deep brain stimulation (VIM-DBS): People aged 18–89 with an essential tremor diagnosis who have working deep brain stimulation devices on both sides of the brain (in the VIM area), and who can walk independently and make their own decisions. (Note: this group will not undergo brain stimulation treatment called TMS as part of the trial.)
- Group 7 – Parkinson's disease without deep brain stimulation, for a specific brain stimulation study (EEG-HD-tACS): People aged 18–89 with a Parkinson's disease diagnosis, a memory and thinking score of 23–30 on a standard test (MoCA), whose Parkinson's medication has been stable, who can walk independently and make their own decisions, and who have no history of seizures.
- Comparison groups (healthy and other participants): Several comparison groups may also be recruited, including healthy adults aged 18–89 matched in age to Parkinson's participants (confirm with trial site), and one subgroup of healthy individuals with a wider age range of 35–99 years (confirm with trial site). Age ranges within comparison groups are designed to align with the ages of Parkinson's participants in the study.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People diagnosed with Lewy Body dementia, Alzheimer's disease, drug-caused Parkinson's-like symptoms, Parkinson's-plus syndromes, or colour-blindness, or who are currently taking experimental/investigational drugs, or who have hearing loss.
- People with a history of neuropsychiatric conditions such as schizophrenia or depression.
- For the TMS part of the study: people with Parkinson's disease who have deep brain stimulation devices, and anyone with a history of seizure disorders.
- For the HD-tACS part of the study: people with Parkinson's disease who have deep brain stimulation devices, and anyone with a history of seizure disorders.
- Comparison group – Alzheimer's disease and Lewy Body dementia patients: people with these diagnoses will be recruited separately as a comparison group for cognitive tasks only (confirm with trial site for how this group fits into the study).
- Comparison group – healthy older adults: people with any neurological disorder, including epilepsy, would not be eligible to join this healthy control group.
- Comparison group – mild traumatic brain injury (mTBI) patients: people with mTBI will be recruited separately as a comparison group for cognitive tasks (confirm with trial site).
- Comparison group – 16p deletion Autism patients: people with this form of autism will be recruited separately as a comparison group for cognitive tasks (confirm with trial site).
- Comparison group – people with brain lesions: people with brain lesions will be recruited separately as a comparison group for cognitive tasks (confirm with trial site).
- Comparison group – older adults with mood disorders: people with mood disorders will be recruited separately as a comparison group for cognitive tasks (confirm with trial site).
- Comparison group – healthy young and middle-aged adults (aged 18–60): people with any neurological disorder, including epilepsy, would not be eligible to join this healthy control group.
- Comparison group – mothers of healthy young adult control participants: this specific group may also be recruited as a comparison group (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
By Invitation
Phase
Not Applicable
Sponsor
Nandakumar Narayanan
Registry
ClinicalTrials.gov
Start date
25 September 2017
Est. completion
31 December 2029
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Changes to EEG physiological parameters (mid-frontal delta/theta activity) due to Parkinson's disease (PD) at Day 1
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.